Bellevue Group Ag Arcus Biosciences, Inc. Transaction History

Bellevue Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $347,429 - $629,781	-17,636 Reduced 21.12%	65,864 $1.36 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $153,318 - $198,462	-6,600 Reduced 7.33%	83,500 $2.18 Million
Q2 2022 Aug 11, 2022	SELL	$17.23 - $37.73 $372,168 - $814,967	-21,600 Reduced 19.34%	90,100 $2.28 Million
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $699,864 - $1.01 Million	24,200 Added 27.66%	111,700 $3.53 Million
Q4 2021 Feb 10, 2022	SELL	$31.38 - $48.47 $225,936 - $348,984	-7,200 Reduced 7.6%	87,500 $3.54 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $530,521 - $742,296	19,700 Added 26.27%	94,700 $3.3 Million
Q1 2021 May 12, 2021	BUY	$26.16 - $41.39 $627,840 - $993,360	24,000 Added 47.06%	75,000 $2.11 Million
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $867,000 - $1.65 Million	51,000 New	51,000 $1.32 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.